Bacillus Calmette-Guérin therapy-associated granulomatous prostatitis mimicking prostate cancer on MRI: A case report and literature review
- Authors:
- Nicolaie Suditu
- Dragos Negru
View Affiliations
Affiliations: Department of Urology, Dr. C.I. Parhon Hospital, 700503 Iasi, Romania, Department of Radiology, St. Spiridon Hospital, Gr. T. Popa University of Medicine, 700111 Iasi, Romania
- Published online on: September 19, 2014 https://doi.org/10.3892/mco.2014.422
-
Pages:
249-251
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Granulomatous prostatitis following bacillus Calmette‑Guérin (BCG) immunotherapy is a well‑known pathological entity, developing following initiation of BCG therapy as a prophylactic measure against the recurrence of non‑muscle invasive bladder cancer. In addition, there are certain imaging similarities between granulomatous prostatitis and prostate cancer, including hypoechoic area on transrectal ultrasonography and low T2 signal intensity in some prostate areas on magnetic resonance imaging (MRI). This is the report of a case exhibiting a perfect imaging cross‑match between granulomatous prostatitis and potential prostate cancer on repeated MRI exams, adding two supplementary aspects to the already known similarities, namely progressive restricted diffusion and increased contrast enhancement, which are specific to prostate cancer.
View References
|
1
|
Babjuk M, Burger M, Zigeuner R, et al:
European Association of Urology: EAU guidelines of
non-muscle-invasive urothelial carcinoma of the bladder: update
2013. Eur Urol. 64:639–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lamm DL, Blumenstein BA, Crissman JD, et
al: Maintenance bacillus Calmette-Guerin immunotherapy for
recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma
of the bladder: a randomized Southwest Oncology Group Study. J
Urol. 163:1124–1129. 2000. View Article : Google Scholar
|
|
3
|
Heidenreich A, Bellmunt J, Bolla M, et al:
European Association of Urology: EAU guidelines on prostate cancer.
Part 1: screening, diagnosis, and treatment of clinically localised
disease. Eur Urol. 59:61–71. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lamm DL, Stogdill VD, Stogdill BJ and
Crispen RG: Complications of bacillus Calmette-Guérin immunotherapy
in 1,278 patients with bladder cancer. J Urol. 135:272–274.
1986.
|
|
5
|
LaFontaine PD, Middelman BR, Graham SD Jr
and Sanders WH: Incidence of granulomatous prostatitis and
acid-fast bacilli after intravesical BCG therapy. Urology.
49:363–366. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oates RD, Stilmant MM, Freedlund MC and
Siroky MB: Granulomatous prostatitis following bacillus
Calmette-Guérin immunotherapy of bladder cancer. J Urol.
140:751–754. 1988.
|
|
7
|
Lamm DL, van der Meijden PM, Morales A, et
al: Incidence and treatment of complication of bacillus
Calmette-Guérin intravesical therapy in superficial bladder cancer.
J Urol. 147:596–600. 1992.
|
|
8
|
Leibovici D, Zisman A, Chen-Levyi Z, et
al: Elevated prostate specific antigen serum levels after
intravesical instillation of bacillus Calmette-Guérin. J Urol.
164:1546–1549. 2000.PubMed/NCBI
|
|
9
|
Ma W, Kang SK, Hricak H, Gerst SR and
Zhang J: Imaging appearance of granulomatous disease after
intravesical Bacille Calmette-Guérin (BCG) treatment of bladder
carcinoma. AJR Am J Roentgenol. 192:1494–1500. 2009.PubMed/NCBI
|
|
10
|
Witjes JA, Palou J, Soloway M, et al:
Clinical practice recommendations for the prevention and management
of intravesical therapy-associated adverse events. Eur Urol. Suppl
7:667–674. 2008. View Article : Google Scholar
|
|
11
|
Barentsz JO, Richenberg J, Clements R, et
al: European Society of Urogenital Radiology: ESUR prostate MR
guidelines 2012. Eur Radiol. 22:746–757. 2012. View Article : Google Scholar : PubMed/NCBI
|
